The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 25, 2014

Filed:

Nov. 23, 2011
Applicants:

John Mcdonald, Arnoldsville, GA (US);

Nathan John Bowen, Atlanta, GA (US);

Lijuan Wang, Smyrna, GA (US);

Inventors:

John McDonald, Arnoldsville, GA (US);

Nathan John Bowen, Atlanta, GA (US);

LiJuan Wang, Smyrna, GA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); A61K 9/51 (2006.01); A61K 45/06 (2006.01); A61K 31/713 (2006.01); A61K 31/7105 (2006.01); C12N 15/113 (2010.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7105 (2013.01); C12N 2310/141 (2013.01); A61K 9/51 (2013.01); A61K 45/06 (2013.01); A61K 31/713 (2013.01); A61K 9/5138 (2013.01); C12N 15/113 (2013.01); A61K 9/00 (2013.01);
Abstract

The present invention provides a method of treating an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to treat the ovarian cancer. Also provided are methods of preventing metastasis of an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to prevent metastasis. Further provided are methods of sensitizing an ovarian cancer to a cytotoxic therapy, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to sensitize the ovarian cancer to the cytotoxic therapy. The invention also contemplates methods of reducing epithelial-to-mesenchymal transition (EMT) in an ovarian cancer or cancer cell as well as methods of inducing mesenchymal-to-epithelial transition (MET).


Find Patent Forward Citations

Loading…